We previously reported that A59T tumors were responsive to EGFR inhibition in a single patient with metastatic chemorefractory colorectal cancer, challenging the one-size-fits-all approach for using KRAS mutation as a negative predictor for anti-EGFR therapy, and that observation stimulated this wider attempt at evaluation. This evidence concerns the gene EGFR and colorectal cancer.